Background: Oral vinorelbine administered at the maximum tolerated dose has already showed activity and a good safety profile in advanced non-small-cell lung cancer (NSCLC). The MA.NI.LA study was a phase II, multicenter, randomized, controlled trial that aimed to assess the effects of a 'switched maintenance' regimen with oral metronomic vinorelbine (OMV) in patients with NSCLC who had not progressed after first-line platinum-based chemotherapy.
Patients And Methods: Patients were randomly assigned in a 1:1 ratio to either OMV (50 mg three-times weekly) as maintenance treatment or best supportive care (BSC). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective disease control rate (DCR, CR + PR + SD), safety and quality of life.
Results: In total, 61 and 59 patients were assigned to OMV and BSC, respectively. At a median follow-up of 23.9 (IQR 10.2-38.2) months, patients treated with OMV reported a significantly lower progression rate compared to patient in the BSC arm (89% [54/61] vs 96% [56/58]; HR 0.73; 90% CI 0.53-0.999, p = 0.049). Median PFS for patients treated with vinorelbine was 4.3 months (95% CI 2.8-5.6) vs 2.8 months (95% CI 1.9-4.5) for patients receiving BSC. This benefit was specifically evident in patients aged ≥70 years, in current smokers, and in those who reported disease stabilization as best response to induction chemotherapy. OS and response rate and quality of life were similar in the two arms. Drop-out rate for major toxicity with OMV was unexpectedly high (25%, 14/61) mainly due to grade 3-4 neutropenia (11%, 7/61). Conclusions In patients with unselected NSCLC achieving disease control after platinum-based chemotherapy switch maintenance therapy with OMV prolonged PFS compared to BSC; however, the optimal dose of OMV requires further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lungcan.2019.04.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer After Trastuzumab Failure (PROVE): A Prospective Phase 2 Study.
Cancer Res Treat
August 2024
Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Article Synopsis
- A study evaluated the effectiveness and safety of pyrotinib combined with metronomic vinorelbine for patients with HER2-positive advanced breast cancer who did not respond to trastuzumab treatment.
- The trial involved 36 patients and reported a median progression-free survival (PFS) of 13.5 months, with an overall response rate (ORR) of 38.9% and a disease control rate (DCR) of 83.3%.
- Common side effects included diarrhea and vomiting, but no severe adverse events were noted, indicating a promising treatment option for these patients.
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.
Nat Med
September 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- A phase 2 clinical trial explored the efficacy of metronomic chemotherapy combined with PD-1 blockade in patients with metastatic HER2-negative breast cancer, comparing it to conventional chemotherapy.
- The study found that the metronomic VEX regimen (which includes vinorelbine, cyclophosphamide, and capecitabine) and conventional cisplatin both had high disease control rates (DCR) of around 69.7% and 73.7%, respectively, with VEX showing the longest median progression-free survival of 6.6 months.
- Overall, all treatment regimens were well tolerated, with common side effects including nausea and neutropenia, and results suggest that metronomic VEX with PD
Efficacy and safety of metronomic oral vinorelbine and its combination therapy as second- and later-line regimens for advanced non-small-cell lung cancer: a retrospective analysis.
Clin Transl Oncol
December 2024
Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuma Street, Jinan District, Fuzhou, 350014, China.
Objective: This retrospective analysis aimed to evaluate the efficacy and adverse reactions of metronomic oral vinorelbine and its combination therapy as second- and later-line regimens for advanced non-small-cell lung cancer (NSCLC).
Methods: NSCLC patients undergoing metronomic oral vinorelbine as second- and later-line regimens in Fujian Cancer Hospital from October 2018 to October 2022 were enrolled, and patients' demographic and clinical characteristics were collected. The efficacy and safety of metronomic oral vinorelbine monotherapy and its combination therapy regimens were compared.
Chemotherapy in pediatric low-grade gliomas (PLGG).
Childs Nerv Syst
October 2024
Division of Pediatric Neuro-Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Pediatric low-grade gliomas (PLGG) are commonly treated with a combination of surgery, radiotherapy, and chemotherapy. Recent trends prioritize reducing long-term morbidities, particularly in younger patients. While historically chemotherapy was reserved for cases progressing after radiotherapy, evolving recommendations now advocate for its early use, particularly in younger age groups.
View Article and Find Full Text PDFSingle-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Breast
April 2024
Phase 1 Clinical Research Unit, ASST Monza, via Pergolesi 33, 20052 Monza, Italy; Medical Oncology, University of Milano-Bicocca, Piazza dell'Ateneo Nuovo, 1, 20126, Milan, Italy. Electronic address:
Article Synopsis
- Single-agent oral vinorelbine is a recommended treatment for advanced breast cancer that has progressed after hormone therapy, with metronomic dosing potentially offering better safety and efficacy.
- A phase II trial compared metronomic administration (50 mg three times a week) with a weekly schedule (60 mg/m initially, increasing to 80 mg/m) in 163 patients, measuring disease control rate (DCR).
- Results showed DCR was 63.4% for the metronomic group and 72.8% for the weekly group, with the weekly regimen resulting in longer progression-free and overall survival but also more side effects; both schedules are viable options for treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!